Its medical device sales fell short of Wall Street projections, causing J&J to plan an exit strategy for certain markets and stop selling some products under its orthopedic business.
Johnson & Johnson reported $2.2 billion in orthopedic sales in the third quarter of the year, up 3.4% from the same period last year. Its hip, knee, spine and sports medicine segments also saw year-over-year growth.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
